Applied Genetic Technologies Corporation Company Profile (NASDAQ:AGTC)

About Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Applied Genetic Technologies Corporation logoApplied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AGTC
  • CUSIP: N/A
  • Web: www.agtc.com
Capitalization:
  • Market Cap: $85.86 million
  • Outstanding Shares: 18,076,000
Average Prices:
  • 50 Day Moving Avg: $5.08
  • 200 Day Moving Avg: $6.40
  • 52 Week Range: $4.60 - $17.00
P/E:
  • Trailing P/E Ratio: 11.34
  • Foreward P/E Ratio: -11.59
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $43.24 million
  • Price / Sales: 1.99
  • Book Value: $6.55 per share
  • Price / Book: 0.73
Profitability:
  • EBIDTA: $8.04 million
  • Net Margins: 17.61%
  • Return on Equity: 6.62%
  • Return on Assets: 4.49%
Debt:
  • Current Ratio: 4.24%
  • Quick Ratio: 4.24%
Misc:
  • Average Volume: 199,690 shs.
  • Beta: 1.71
  • Short Ratio: 0.91
 
Frequently Asked Questions for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

What is Applied Genetic Technologies Corporation's stock symbol?

Applied Genetic Technologies Corporation trades on the NASDAQ under the ticker symbol "AGTC."

How were Applied Genetic Technologies Corporation's earnings last quarter?

Applied Genetic Technologies Corporation (NASDAQ:AGTC) issued its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by $0.04. The firm had revenue of $8.39 million for the quarter, compared to analyst estimates of $10.39 million. Applied Genetic Technologies Corporation had a return on equity of 6.62% and a net margin of 17.61%. Applied Genetic Technologies Corporation's revenue for the quarter was down 30.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.11 EPS. View Applied Genetic Technologies Corporation's Earnings History.

Where is Applied Genetic Technologies Corporation's stock going? Where will Applied Genetic Technologies Corporation's stock price be in 2017?

9 analysts have issued twelve-month target prices for Applied Genetic Technologies Corporation's stock. Their predictions range from $11.00 to $16.00. On average, they anticipate Applied Genetic Technologies Corporation's share price to reach $14.63 in the next twelve months. View Analyst Ratings for Applied Genetic Technologies Corporation.

What are analysts saying about Applied Genetic Technologies Corporation stock?

Here are some recent quotes from research analysts about Applied Genetic Technologies Corporation stock:

  • 1. According to Zacks Investment Research, "Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida. " (7/25/2017)
  • 2. Rodman & Renshaw analysts commented, "A leader in AAV development; first-in-man data soon and critical to investment case. AGTC's AAV (adeno-associated virus) platform is based on a proprietary viral composition and manufacturing process that are backed by strong intellectual property positions. AGTC has the capability to target specific tissue types and drive gene expression appropriate for that tissue. We believe that there is great potential to treat an array of disorders that are monogenic (single gene) and autosomal recessive or X-linked. The company is currently targeting orphan ophthalmological indications with the goal of addressing the underlying biology of the disorder.Plenty of cash to fund development. We believe the preclinical data in hand support our projected outcome for positive results from the ongoing clinical programs. We are quickly approaching critical first-in-man data in mid-2017 from the company's lead program in XLRS and initial clinical data from the ACHM program by year-end 2017. We believe these data should help correct the valuation disconnect we call to investors' attention where the stock is trading below the company's cash balance, primarily due to the early stage nature of the platform. Additionally, the company has approximately two years of cash on hand to deliver to our development projections; furthermore, the trajectory should create inflection points that include the clinical data points mentioned as well as advancing more products into development." (3/15/2017)

Are investors shorting Applied Genetic Technologies Corporation?

Applied Genetic Technologies Corporation saw a decrease in short interest in June. As of June 30th, there was short interest totalling 253,618 shares, a decrease of 61.6% from the June 15th total of 659,977 shares. Based on an average trading volume of 427,007 shares, the short-interest ratio is currently 0.6 days. Approximately 2.2% of the shares of the stock are sold short.

Who are some of Applied Genetic Technologies Corporation's key competitors?

Who are Applied Genetic Technologies Corporation's key executives?

Applied Genetic Technologies Corporation's management team includes the folowing people:

  • Scott Koenig M.D., Ph.D., Chairman of the Board
  • Susan B. Washer, President, Chief Executive Officer, Director
  • Lawrence E. Bullock, Chief Financial Officer
  • Jeffrey D. Chulay M.D., Senior Vice President, Chief Medical Officer
  • Mark Shearman Ph.D., Chief Scientific Officer
  • Stephen B. Potter, Vice president and chief business officer
  • Michael H. Goldstein, Chief Medical Officer
  • David R. Guyer M.D., Director
  • Ivana Magovcevic-Liebisch Ph.D. J.D., Director
  • Anne M. VanLent, Director

Who owns Applied Genetic Technologies Corporation stock?

Applied Genetic Technologies Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include InterWest Venture Management Co (8.05%), Acadian Asset Management LLC (3.92%), Municipal Employees Retirement System of Michigan (1.03%), Steinberg Global Asset Management (0.61%), Russell Investments Group Ltd. (0.43%) and Bank of Montreal Can (0.33%). Company insiders that own Applied Genetic Technologies Corporation stock include Ivana Magovcevic, Jeffrey D Chulay, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Institutional Ownership Trends for Applied Genetic Technologies Corporation.

Who sold Applied Genetic Technologies Corporation stock? Who is selling Applied Genetic Technologies Corporation stock?

Applied Genetic Technologies Corporation's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Applied Genetic Technologies Corporation.

Who bought Applied Genetic Technologies Corporation stock? Who is buying Applied Genetic Technologies Corporation stock?

Applied Genetic Technologies Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan, Steinberg Global Asset Management, InterWest Venture Management Co and Bank of Montreal Can. Company insiders that have bought Applied Genetic Technologies Corporation stock in the last two years include Ivana Magovcevic, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Insider Buying and Selling for Applied Genetic Technologies Corporation.

How do I buy Applied Genetic Technologies Corporation stock?

Shares of Applied Genetic Technologies Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Applied Genetic Technologies Corporation's stock price today?

One share of Applied Genetic Technologies Corporation stock can currently be purchased for approximately $4.75.


MarketBeat Community Rating for Applied Genetic Technologies Corporation (NASDAQ AGTC)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  267
MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Applied Genetic Technologies Corporation (NASDAQ:AGTC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $14.63 (207.89% upside)

Analysts' Ratings History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/10/2017HC WainwrightSet Price TargetBuy$16.00LowView Rating Details
5/10/2017Cantor FitzgeraldSet Price TargetHold$15.00LowView Rating Details
5/11/2017Stifel NicolausLower Price TargetBuy -> Buy$18.00 -> $15.00HighView Rating Details
3/15/2017Rodman & RenshawInitiated CoverageBuy -> Buy$16.00HighView Rating Details
2/9/2017WedbushReiterated RatingOutperform$15.00N/AView Rating Details
2/9/2017BMO Capital MarketsLower Price TargetBuy$20.00 -> $14.00N/AView Rating Details
11/9/2016Roth CapitalUpgradeNeutral -> Buy$12.00 -> $15.00N/AView Rating Details
9/26/2016Janney Montgomery ScottUpgradeSell -> Neutral$11.00N/AView Rating Details
9/13/2016Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
1/10/2016Chardan CapitalReiterated RatingBuy$25.00N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Earnings by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Earnings History by Quarter for Applied Genetic Technologies Corporation (NASDAQ AGTC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q3 2017($0.01)($0.05)$10.39 million$8.39 millionViewN/AView Earnings Details
2/8/2017Q217$0.02$0.11$11.10 million$10.90 millionViewListenView Earnings Details
11/8/2016Q117($0.10)$0.20$10.21 million$11.80 millionViewListenView Earnings Details
9/12/2016Q416$0.07$0.15$13.10 million$12.10 millionViewListenView Earnings Details
5/9/2016Q3$0.05$0.11$12.98 million$12.00 millionViewN/AView Earnings Details
2/8/2016Q216($0.19)$0.17$8.76 million$12.20 millionViewN/AView Earnings Details
11/5/2015Q1($0.20)($0.53)$5.91 million$11.06 millionViewN/AView Earnings Details
9/10/2015Q415($0.41)($0.48)$0.63 million$0.71 millionViewN/AView Earnings Details
5/11/2015Q315($0.33)($0.38)$0.59 million$0.28 millionViewN/AView Earnings Details
2/11/2015Q215($0.39)($0.28)$0.45 million$0.65 millionViewN/AView Earnings Details
11/12/2014Q115($0.29)($0.34)$258.00 million$705.00 millionViewN/AView Earnings Details
9/26/2014Q414($0.29)($0.32)$0.23 million$0.12 millionViewN/AView Earnings Details
5/14/2014Q114($0.37)($25.45)$0.15 million$0.23 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
2017 EPS Consensus Estimate: ($0.36)
2018 EPS Consensus Estimate: ($0.94)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.45)$0.09($0.18)
Q2 20172($0.04)($0.02)($0.03)
Q3 20172($0.14)$0.04($0.05)
Q4 20172($0.16)($0.04)($0.10)
Q1 20181($0.12)($0.12)($0.12)
Q2 20181$0.08$0.08$0.08
Q3 20181($0.27)($0.27)($0.27)
Q4 20181($0.63)($0.63)($0.63)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 61.55%
Insider Trades by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Institutional Ownership by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Insider Trades by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2016Ivana MagovcevicDirectorBuy3,000$9.63$28,890.00View SEC Filing  
11/1/2016Jeffrey D ChulayVPSell1,000$7.05$7,050.00View SEC Filing  
9/22/2016Mark S ShearmanInsiderBuy3,000$8.87$26,610.00View SEC Filing  
9/20/2016Stephen W PotterInsiderBuy1,400$8.89$12,446.00View SEC Filing  
9/19/2016Lawrence E BullockCFOBuy10,000$8.75$87,500.00View SEC Filing  
2/23/2015Plc GlaxosmithklineMajor ShareholderSell503,150$22.00$11,069,300.00View SEC Filing  
1/23/2015Daniel L MenichellaVPSell1,996$24.90$49,700.40View SEC Filing  
12/22/2014Daniel L MenichellaVPSell9,000$20.83$187,470.00View SEC Filing  
4/1/2014Interwest Partners Viii LpMajor ShareholderBuy75,376$12.00$904,512.00View SEC Filing  
4/1/2014Jill CarrollDirectorBuy103,762$12.00$1,245,144.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Latest Headlines for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Source:
DateHeadline
americanbankingnews.com logoApplied Genetic Technologies Corp (AGTC) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - July 25 at 11:28 PM
americanbankingnews.com logoApplied Genetic Technologies Corp (AGTC) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 25 at 11:28 AM
americanbankingnews.com logo Brokerages Anticipate Applied Genetic Technologies Corporation (AGTC) Will Post Quarterly Sales of $12.36 Million
www.americanbankingnews.com - July 23 at 8:30 AM
americanbankingnews.com logoApplied Genetic Technologies Corporation (AGTC) Expected to Announce Earnings of $0.11 Per Share
www.americanbankingnews.com - July 21 at 6:28 PM
americanbankingnews.com logoComparing Gilead Sciences (GILD) & Applied Genetic Technologies Corporation (AGTC)
www.americanbankingnews.com - July 16 at 7:46 AM
americanbankingnews.com logoApplied Genetic Technologies Corporation (NASDAQ:AGTC) Sees Large Drop in Short Interest
www.americanbankingnews.com - July 16 at 7:06 AM
finance.yahoo.com logoETFs with exposure to Applied Genetic Technologies Corp. : July 13, 2017
finance.yahoo.com - July 13 at 4:18 PM
americanbankingnews.com logoApplied Genetic Technologies Corporation (NASDAQ:AGTC) Downgraded by Zacks Investment Research
www.americanbankingnews.com - July 11 at 6:02 PM
finance.yahoo.com logoETFs with exposure to Applied Genetic Technologies Corp. : July 3, 2017
finance.yahoo.com - July 3 at 3:33 PM
americanbankingnews.com logoApplied Genetic Technologies Corporation (AGTC) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 30 at 11:04 AM
americanbankingnews.com logoApplied Genetic Technologies Corporation (AGTC) Expected to Announce Quarterly Sales of $12.36 Million
www.americanbankingnews.com - June 29 at 11:04 AM
americanbankingnews.com logoApplied Genetic Technologies Corporation (AGTC) Expected to Post Earnings of $0.11 Per Share
www.americanbankingnews.com - June 27 at 2:20 PM
finance.yahoo.com logoETFs with exposure to Applied Genetic Technologies Corp. : June 19, 2017
finance.yahoo.com - June 19 at 3:26 PM
finance.yahoo.com logoApplied Genetic Technologies Corp. :AGTC-US: Earnings Analysis: Q3, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 3:56 PM
reuters.com logoBRIEF-Applied Genetic Technologies updates on clinical development of AGTC-402
www.reuters.com - June 15 at 4:58 PM
finance.yahoo.com logoIND-Enabling Study Data Published in Human Gene Therapy Clinical Development Support Clinical Development of AGTC-402 for the Treatment of CNGA3-deficient Achromatopsia
finance.yahoo.com - June 15 at 4:57 PM
americanbankingnews.com logoGalmed Pharmaceuticals (GLMD) versus Applied Genetic Technologies Corporation (AGTC) Critical Analysis
www.americanbankingnews.com - June 13 at 7:44 AM
americanbankingnews.com logoApplied Genetic Technologies Corporation (AGTC) PT Set at $16.00 by HC Wainwright
www.americanbankingnews.com - June 11 at 10:52 PM
streetinsider.com logoApplied Genetic Technologies (AGTC) Phase 1/2 XLRS Study Generally Well Tolerated with Good Safety Profile
www.streetinsider.com - June 9 at 8:36 PM
finance.yahoo.com logoAGTC Announces Topline Safety Data for X-Linked Retinoschisis Phase 1/2 Study
finance.yahoo.com - June 8 at 8:43 PM
finance.yahoo.com logoData Published in Molecular Therapy Demonstrate Five-Year Response Following a Single Dose of an Investigational Gene-Based Therapy for Alpha-1 Antitrypsin (AAT) Deficiency
finance.yahoo.com - June 8 at 3:41 PM
americanbankingnews.com logoApplied Genetic Technologies Corp (AGTC) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 5 at 9:36 AM
americanbankingnews.com logo$12.36 Million in Sales Expected for Applied Genetic Technologies Corp (AGTC) This Quarter
www.americanbankingnews.com - June 3 at 9:00 AM
americanbankingnews.com logo$0.11 EPS Expected for Applied Genetic Technologies Corp (AGTC) This Quarter
www.americanbankingnews.com - June 1 at 12:30 PM
americanbankingnews.com logoFY2017 EPS Estimates for Applied Genetic Technologies Corp (AGTC) Reduced by Analyst
www.americanbankingnews.com - May 15 at 8:54 AM
americanbankingnews.com logoApplied Genetic Technologies Corp (AGTC) Price Target Lowered to $15.00 at Stifel Nicolaus
www.americanbankingnews.com - May 14 at 12:32 AM
americanbankingnews.com logoBrokers Offer Predictions for Applied Genetic Technologies Corp's Q2 2018 Earnings (AGTC)
www.americanbankingnews.com - May 12 at 4:50 PM
americanbankingnews.com logoApplied Genetic Technologies Corp (AGTC) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 11 at 4:21 PM
businesswire.com logoAxcella Announces the Appointment of Ivana Magovcevic-Liebisch, Ph.D., J.D., as Executive Vice President, Chief Strategy and Corporate Development Officer
www.businesswire.com - May 11 at 3:39 PM
reuters.com logoBRIEF-Applied Genetic Technologies quarterly revenue $8.4 million
www.reuters.com - May 11 at 3:39 PM
finance.yahoo.com logoAGTC Presents New Data on its AAV-Based Gene Therapies for the Treatment of Achromatopsia and X-Linked Retinitis Pigmentosa at the American Society of Gene and Cell Therapy 20th Annual Meeting
finance.yahoo.com - May 11 at 3:39 PM
americanbankingnews.com logoApplied Genetic Technologies Corp (AGTC) Given a $15.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 11 at 2:56 PM
americanbankingnews.com logoApplied Genetic Technologies Corp (AGTC) Issues Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - May 10 at 9:14 PM
finance.yahoo.com logoAGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2017
finance.yahoo.com - May 10 at 8:35 PM
finance.yahoo.com logoApplied Genetic Technologies posts 3Q loss
finance.yahoo.com - May 10 at 8:35 PM
nasdaq.com logoAGTC and Collaborators Present New Data on the Natural History of X-Linked Retinoschisis (XLRS) at
www.nasdaq.com - May 10 at 3:35 PM
finance.yahoo.com logoInvestor Network: Applied Genetic Technologies Corp. to Host Earnings Call
finance.yahoo.com - May 10 at 3:35 PM
americanbankingnews.com logo$9.55 Million in Sales Expected for Applied Genetic Technologies Corp (AGTC) This Quarter
www.americanbankingnews.com - May 10 at 11:34 AM
americanbankingnews.com logoApplied Genetic Technologies Corp (AGTC) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 9 at 10:52 AM
finance.yahoo.com logoAGTC and Collaborators Present New Data on the Natural History of X-Linked Retinoschisis (XLRS) at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
finance.yahoo.com - May 9 at 9:24 AM
americanbankingnews.com logoApplied Genetic Technologies Corp (AGTC) Expected to Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - May 8 at 10:50 AM
americanbankingnews.com logoApplied Genetic Technologies Corp (AGTC) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - May 8 at 8:32 AM
finance.yahoo.com logoAGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 10, 2017
finance.yahoo.com - May 2 at 3:27 PM
americanbankingnews.com logoSomewhat Favorable Media Coverage Unlikely to Affect Applied Genetic Technologies Corp (AGTC) Share Price
www.americanbankingnews.com - May 2 at 10:14 AM
finance.yahoo.com logoETFs with exposure to Applied Genetic Technologies Corp. : May 1, 2017
finance.yahoo.com - May 2 at 6:52 AM
reuters.com logoBRIEF-Applied Genetic Technologies says on April 26 CFO Lawrence Bullock said will retire in near future
www.reuters.com - May 1 at 3:27 PM
streetinsider.com logoApplied Genetic Technologies (AGTC) CFO Lawrence E. Bullock to Retire
www.streetinsider.com - May 1 at 3:27 PM
americanbankingnews.com logoApplied Genetic Technologies Corp (AGTC) Earns News Impact Score of 0.31
www.americanbankingnews.com - April 28 at 11:02 AM
americanbankingnews.com logoApplied Genetic Technologies Corp (AGTC) Receiving Somewhat Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 25 at 2:30 PM
americanbankingnews.com logoSomewhat Critical Media Coverage Likely to Affect Applied Genetic Technologies Corp (AGTC) Stock Price
www.americanbankingnews.com - April 21 at 9:01 AM

Social

Chart

Applied Genetic Technologies Corporation (AGTC) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff